GlaxoSmithKline开发出增加ITP患者血小板计数

 
 
一种正在研制之中的新药，能够显著升高慢性免疫性血小板减少性紫癜（ITP）患者的血小板数量。

小分子血小板生成素受体eltrombopag，是由GlaxoSmithKline公司(London, UK)研制开发的，其II期临床试验数据显示， 这种化合物能够有效增加ITP患者的血小板计数。这种疾病表现为明显的血小板破坏，频繁的自发性淤血、粘膜出血，在严重病例，甚至会发生颅内出血和严重的大出血。

Eltrombopag被认为能够刺激巨核细胞的增殖和分化，巨核细胞是来自骨髓的细胞能够转化为血小板，因此Eltrombopag被认为是血小板生长因子。因为这是一种小分子，因此该药导致免疫反应的可能，要比大蛋白分子 小很多。
 
Increasing Platelet Count in ITP
 
A new drug under investigation significantly increases blood platelet counts in patients with chronic immune thrombocytopenic purpura (ITP).

Data from a Phase II study of eltrombopag, an investigational small-molecule thrombopoietin receptor being developed by GlaxoSmithKline (London, UK), demonstrated that the compound was effective in increasing platelet counts in ITP. The disorder is marked by platelet destruction, episodes of frequent spontaneous bruising, mucosal bleeding, and in severe cases, intracranial hemorrhage and acute episodes of severe bleeding.

Eltrombopag is thought to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets, and thus is considered a platelet growth factor. Because it is a small molecule, the drug has less potential than large protein molecules for causing an immune system reaction.